Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). “The Terns acquisition reflects Merck’s continued focus on science‑driven, value‑enhancing business development aimed at bringing meaningful innovation to patients,” said Robert M. Davis, chairman and chief executive officer, Merck. “We believe TERN‑701 has the potential to become a differentiated treatment

Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment Disruptions May 5, 2026 -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced that it has secured regulatory authorization in Spain for its Phase 2a CLEER Trial of HT-001, while concurrently reporting encouraging interim clinical results demonstrating meaningful efficacy and safety in

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today highlighted preclinical data for its lead candidate, EB-003, a dual 5-HT2A and 5-HT1B modulator, in which a single dose of EB-003 significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05). These results indicate a rapid reduction in conditioned fear response in

Strategic investment brings together RTI's scientific leadership and Navidence AI-native platform to improve research quality, reproducibility, and patient outcomes across the life sciences May 5, 2026 -- Independent scientific research institute RTI International today announced a partnership and strategic equity investment in Navidence, a technology and knowledge content company focused on defining health data and enabling more efficient, transparent and scientifically rigorous clinical resea

May 05, 2026 -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a European patent application for innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (PTSD) and other mental health disorders. The Euro

The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable benefit risk profile for AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) for the treatment of patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC), based on the CAPItello-281 Phase III trial. The Committee voted 7 to 1, with 1 abstaining. In August 2025, the FDA accepted the supplemental New Drug

AI-Driven Field Insights Drive Pharmaceutical Brand Performance in World’s Largest Market April 30, 2026 -- KAI Conversations, an AI-powered conversation intelligence platform purpose-built for the pharmaceutical industry, today announced a strategic partnership with Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, to bring AI-driven field insights to the U.S. biopharma market. Pharmaceutical companies invest an estimated 30–50% of revenue in field teams,

Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden Enpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standards ELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links bet

April 30, 2026 — La Jolla Labs,Inc. today announced that the first patient has been treated with GBFsen, a custom-designed antisense oligonucleotide (ASO) therapy developed to target a TDP-4 patient-specific mutation associated with an inherited, ultra-rare form of amyotrophic lateral sclerosis (ALS). The patient was diagnosed one year ago with a rapidly progressive form of ALS driven by a mutation in the prion-like domain of TDP-43. With no approved therapies, no clinical protocols, and no es

China-based Huahui Health has granted BeOne Medicines (Nasdaq: ONC) a global exclusive option over HH160, a preclinical trispecific antibody targeting PD-1, CTLA-4, and VEGF-A simultaneously, in a cancer immunotherapy collaboration that carries a headline value of up to USD 2.02 billion. Under the agreement, BeOne Medicines (NASDAQ: ONC) pays an upfront USD 20 million to secure the option, with a further USD 100 million due upon formal exercise. Huahui Health, a privately held Beijing-based biop